Neurol. praxi. 2015;16(5):293-295

Pain of mixed etiology in patient with polymorbidity

doc. MUDr. Jiří Kozák, Ph.D.
Centrum pro léčení a výzkum bolestivých stavů při Klinice rehabilitace
a tělovýchovného lékařství 2. LF UK a FN v Motole, Praha

Polymorbid patient with pain is a difficult problem for physicians. It is usually more of the diseases that are accompanied by various types of pain, and is treated with medicaments which have different pharmacologic properties and adverse effects (Slíva, 2011). In these cases it is very important detailed examination of pain etiology and rational use of analgesic treatment (Ambler, 2012). In our case report, we present example of polymorbid middle-aged patient who suffers from serious illnesses, underwents radical surgery on the musculoskeletal system and has a long-term chronic medication therapy, including corticosteroids. Patient is treated with several analgesics, despite its multiple pain are not sufficiently covered. Etiology of pain is mixed. Nociceptive component dominates, but is combined with a neuropathic component. In our department was adjusted pharmacotherapy emphasizing the influence component of neuropathic pain. At the control examination, we noticed reduce pain, lower incidence of adverse events of drugs and signs of improvement in quality of life.

Keywords: polymorbid patient, neuropathic pain, nociceptive pain, analgesics

Published: October 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kozák J. Pain of mixed etiology in patient with polymorbidity. Neurol. praxi. 2015;16(5):293-295.
Download citation

References

  1. Ambler Z. Neuropatická bolest. In: Bolest. Kršiak M, Kozák J, Rokyta R. Praha: Tigis 2012: 233-257.
  2. Bockbrader HN, Wesche D. Pharmacokinetic profile of pregabalin: results of a series of studies. [abstract no. NR378]. 15th Annual Meeting of the American Psychiatric Association; New York, 2004.
  3. Ambler Z. Doporučené postupy pro farmakoterapii neuropatické bolesti. 2011, dostupné z: http://www.farmakoterapie.cz/c2852/farmakoterapie-neuropaticke-bolesti-soucasnadoporuceni.
  4. Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg 2007; 105: 1805-1815. Go to original source... Go to PubMed...
  5. Ghai A, Gupta M, Hooda S, Singla D. Wadhera R. A randomized controlled trial to compare pregabalin with gabapentin for postoperative pain in abdominal hysterectomy. Saudi J. Anaesth 2011; 5: 252-257. Go to original source... Go to PubMed...
  6. Chen H, Lamer TL, Rho RH, et al. Contemporary management of neuropathic pain for the primary care physician. Mayo Clin Proc 2004; 79: 1533-1545. Go to original source... Go to PubMed...
  7. Lauria-Horner BA, Pohl RB. Pregabalin: a new anxiolytic. Expert Opin Investig Drugs 2003; 12: 663-672. Go to original source... Go to PubMed...
  8. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009: CD007076. Go to original source...
  9. Slíva J, Kozák J, Černý R. Farmakoterapie neuropatické bolesti. Praha: Maxdorf Jessenius 2011: 81.
  10. SPC souhrn údajů o přípravku Lyrica-pregabalin, dostupné z : http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000546/WC500046602.pdf.
  11. Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf 2014; 5: 38-56. Go to original source... Go to PubMed...
  12. Wensel TM, Powe KW, Cates ME. Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother 2012; 46: 424-429. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.